Adds details in paragraphs 2,3

Dec 26 (Reuters) - Bristol Myers Squibb BMY.N said on Tuesday it will acquire radiopharmaceutical firm RayzeBio RYZB.O for about $4.1 billion.

Bristol said it will pay $62.50 for each share of RayzeBio in cash, representing a premium of 104% to stock's last close.

RayzeBio shares were halted ahead of the deal announcement.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)

(( Bhanvi.Satija@thomsonreuters.com ; Outside U.S. +91 9873062788; ))

(c) Copyright Thomson Reuters 2023. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Keywords: RAYZEBIO-M&A/BRISTOL-MYERS (UPDATE 1)